Asterias Biotherapeutics Inc (AST) Short Interest Up 19.2% in January
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 430,397 shares, a growth of 19.2% from the January 15th total of 361,141 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average trading volume of 288,497 shares, the days-to-cover ratio is presently 1.5 days.
Shares of NYSEAMERICAN:AST traded up $0.07 on Monday, reaching $0.90. The company had a trading volume of 101,500 shares, compared to its average volume of 172,043. Asterias Biotherapeutics has a 52-week low of $0.51 and a 52-week high of $2.30.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last announced its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.02. The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.11 million.
Separately, Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Thursday, November 15th.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.
Featured Story: Price to Earnings Ratio (PE)
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.